Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine.
Sanders
C
C
Perez
E A
EA
Lawrence
H J
HJ
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000139:chemically induced / Q000150:complications*; D011020:Pneumonia, Pneumocystis / Q000150:complications; D014376:Tuberculosis / Q000150:complications; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine